Diacylglycerol acyl transferase 2 inhibitors

Patent metadata

Field	Value
Publication number	US-11034678-B2
Application number	US-202016793441-A
Country	US
Kind code	B2
Filing date	Feb 18, 2020
Priority date	Aug 19, 2016
Publication date	Jun 15, 2021
Grant date	Jun 15, 2021

Abstract

Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

First claim

What is claimed is:

1. A method for the reduction of at least one point in severity of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis grading scoring systems, reduction of the level of serum markers of nonalcoholic steatohepatitis activity, reduction of nonalcoholic steatohepatitis disease activity or reduction in the medical consequences of nonalcoholic steatohepatitis in humans comprising the step of administering to a human in need of such reduction an effective amount of a compound according to Formula (I) or a pharmaceutically acceptable salt of said compound to a patient in need thereof; wherein the compound of Formula (I) is:

wherein
D 1 and D 2 are each independently N or CH;
R 1 is H, or (C 1 -C 2 )alkyl optionally substituted with one or two substituents each independently selected from fluoro and (C 3 -C 6 )cycloalkyl;
R 2 is H or fluoro;
R 3 is

R 4 is H, cyano, or (C 1 -C 4 )alkyl optionally substituted with one or two substituents each independently selected from —OH and —S(O) 2 R 6 ;
R 5 is H or —OH; and
R 6 is (C 1 -C 4 )alkyl.

2. The method of claim 1 wherein the method reduces portal hypertension, hepatic protein synthetic capability, hyperbilirubinemia, or encephalopathy.

3. The method of claim 1 wherein the compound of Formula (I) is

or a pharmaceutically acceptable salt thereof.

4. The method of claim 2 wherein the compound of Formula (I) is

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 wherein the compound of Formula (I) is

6. The method of claim 2 wherein the compound of Formula (I) is

7. The method of claim 1 wherein the compound of Formula (I) is 2-(5-((3-ethoxpyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof.

8. The method of claim 2 wherein the compound of Formula (I) is 2-(5-((3-ethoxpyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 wherein the compound of Formula (I) is 2-(5-((3-ethoxpyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide.

10. The method of claim 2 wherein the compound of Formula (I) is 2-(5-((3-ethoxpyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide.

Assignees

• Pfizer

Inventors

• Boehm Markus
• Cabral Shawn
• Dowling Matthew S
• Futatsugi Kentaro
• Huard Kim
• Lee Esther Cheng Yin
• Londregan Allyn T
• Polivkova Jana
• Price David A
• Li Qifang

Classifications

• C07D409/14

  containing three or more hetero rings · CPC title

• C07D405/14 Primary

  containing three or more hetero rings · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• C07D401/14 Primary

  containing three or more hetero rings · CPC title